Impetigo News and Research

RSS
Impetigo (sometimes impetaigo) is a superficial bacterial skin infection most common among pre-school children. People who play close contact sports such as rugby, American football and wrestling are also susceptible, regardless of age. Impetigo is not as common in adults. It is also highly contagious. The name derives from the Latin ''impetere'' ("assail"). It is also known as school sores.
Researchers develop new way of testing bacterial resistance to antibiotics

Researchers develop new way of testing bacterial resistance to antibiotics

Researchers characterize S. aureus gene involved in virulence and antibiotic resistance

Researchers characterize S. aureus gene involved in virulence and antibiotic resistance

Eczema can increase patients' risk of developing several other health conditions

Eczema can increase patients' risk of developing several other health conditions

FDA grants CLIA waiver for Alere i Strep A test

FDA grants CLIA waiver for Alere i Strep A test

Alere i Strep A test receives marketing clearance from FDA

Alere i Strep A test receives marketing clearance from FDA

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Ferrer partners with Cipher Pharmaceuticals to bring Ozenoxacin to the Canadian market

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche announces launch of cobas Liat System for on-demand testing in different settings

Rhine-Waal students bag first place in research poster competition at European Detergents Conference

Rhine-Waal students bag first place in research poster competition at European Detergents Conference

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

FDA clears Meridian Bioscience’s new illumigene Group A Strep test

Patients with history of skin infection more likely to develop surgical site infections

Patients with history of skin infection more likely to develop surgical site infections

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

Novabay commences NVC-422 catheter Phase 2 trial to treat UCBE

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

Dermatologists urge athletes to be aware of most common skin infections

Dermatologists urge athletes to be aware of most common skin infections

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay Pharmaceuticals, Galderma expand their multi-year collaboration agreement

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay announces meeting with FDA to discuss Aganocide compound for impetigo

NovaBay third quarter net loss increases to $1.6 million

NovaBay third quarter net loss increases to $1.6 million

NovaBay receives $244,479 QTDP grant for program to treat Impetigo

NovaBay receives $244,479 QTDP grant for program to treat Impetigo